MedTrace Logo

Impact of Ganoderma Lucidum on NRF2 Levels and Antioxidant Status in Metabolic Asscociated Fatty Liver Disease (GL-MAFLD-NRF2 Study)

NCT07564947 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-05-04

No results posted yet for this study

Summary

This RCT investigates the impact of Ganoderma lucidum on antioxidant staus, NRF2 levels and lipid metabolism in individuals with Metabolic Associated Fatty Liver Disease.

Conditions

  • MAFLD
  • Fatty Liver
  • Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD
  • Fatty Liver, Nonalcoholic
  • Fatty Liver Disease
  • Oxidative Stress
  • Inflammation

Interventions

DIETARY_SUPPLEMENT

Starch Placebo

Intervention will invovle the the intake of Starch Placebo capsule

DIETARY_SUPPLEMENT

Ganoderma lucidum

Intervention will involve the intake of Ganoderma lucidum mushroom powder

Sponsors & Collaborators

  • University of Agriculture, Peshawar

    lead OTHER

Principal Investigators

  • Bibi Hajira, PhD · Khyber Medical University Peshawar

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-28
Primary Completion
2027-04-20
Completion
2027-04-20

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07564947 on ClinicalTrials.gov